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-'~ Nitric Oxide Is the Mediator Responsible for (NO) 
Physical Training-Normalized Vasodilstion of 
Eplcardial Coronary Artery During Oevelopment of 
Heart Failure (HF) 
Jie Wang, Gang-Hue Yi, Mathias Knesht, Milton Packer, Daniel Burkhoff. 
Columbia University College of P & S, New York City, NY 
Defective endothelial function of epicardial coronary arteries (decreased 
vasomotion to acetylcholine (Ach) and shear stress), occurs in experimental 
HE This dysfunction can be normalized by chronic physical training (PT), 
The goal of this study was to determine whether this normalization was 
mediated by a restoration of endothelial NO release capacity. Dogs (n = 7) 
were instrumented to measure hemodynamics, circumflex coronary artery 
diameter (CO) and for chrenlc pacing, Do~s were cardiac paced (210 b/rain 
for 3 wks and 240 b/min for the 4th wk) and underwent readmill tralnin9 
(4.4 :E 0.3 knVh, 2 hrs/day) throughout this pedod. Responses of CD to Ach, 
occlusion (Occ) and nitroglycedn (NTG) were examined prior to (control) 
and after the PT-pacing pedod. These responses were also recorded after 
nitro.L-arglnine (NLA, a NO inhibitor). The data (see Table of mean + SE 
values) show that CD responses to Ach and Occ are maintained and that 
these are abolished by NLA at the end of the 4 wk period. 
Baseline (mm) Response (mm) % 
Ach (5 #g/kg) Control 3.32 2:0.23 3.49 2: 0.g3* 5,38 :l: 1.3' 
PT & Pacing 3.652:0.15 3.862:0.16" 5.85 2: 0,8* 
NLA 3.61 2:0.18 3.66-;-0.15 1,792:1.5 
Occ, (30 s) Control 3.35 2:0.24 3.53 2: 0.23* 5.71 2:1.1" 
PT & Pacing 3.65 2:0.14 3.86 2:0.17* 5,44 2:1.1 *
NLA 3.662:0.14 3.682:0.15 0.1 2:0.3 
NTG (25 ~/kg) Control 3.33 4. 0.23 3.59 2: 0.24* 7.79 2:1.6" 
PT& Pacing 3,65±0.14 3.86=1:0.17" 5.694-44* 
NLA 3.592:0.18 3.852:0.16" 5.152:0.96' 
*p < 0,05 from baseline 
ThUS, chronic physical training preserves flow-depandent, endothellum- 
mediated dilation of epicardial coronary artery dudng development of HF 
through a normalized endothelial NO mechanism. 
"p < 0.05 
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1"~"5--2"1 Prostacyclln, but Not Nitric Oxide, Mediates the 
Vasodllator Response to Endothelin-1 in the 
Coronary Circulation 
Jay H. Traverse, Dianne L, Judd, Todd J. Pavek, Melanie J. Crempton, 
Robert J. Bashe. University of Minnesota, Minneapolis, MN 
Endothelin-1 (ET-t) may stimulate the endothelial release of vesodilators 
such as prostacyclin (PGI2) and nitdc oxide (NO) and be capable of causing 
vasodilstion. To investigate ET-1 induced coronary vasodilator activity we 
measured aortic and coronary sinus (CS) levels of ET-1, 6.keto-PGFl= (the 
stable mstabolite of PGI~) and cGMP (an index of NO production) dudng 
Infusions of ET-1 (1, 10, 100 ng/mln x 30 rain) Into the left main coronary 
artery of 13 dogs with a co,ateral-dabendent myocardial region (14% of the 
LV) Myocardial blood flow (MBF) was measured with mlcrospheres. 
ET-1 Dose CS ET-1 CS PGFI= MBF (ml/min,g) 
(ng/min) (pg/ml) (pg/ml) Normal Zone Collateral Zone 
0 4.9 :E 1.7 3722:43 0.822:0.08 0.74:1:0.07 
1 12.3:E4 376 ~60 0,932:0,05 0.65~0.05 
10 73d: 16" 5352:114" 0.92 ~ 0.07" 0.71:/:0.05 
100 175 2: 45" 784-;- 153' 0.61 2: 0.07* 0.484- 0.06" 
ET-1 caused a significant increase in normal zone MBF at a dose of 10 
ng/mln but no change In collateral zone MBF. At 100 ng/min MBF to both 
regions was significantly reduced. ET-1 caused dose-depondent increases In 
CS levels of PGF~=, indicating that ET-1 stimulated PGI2 pmductian. ET-1 had 
no effect on oGMP production. In a separate group of dogs pretreatmant with 
Indomethasin abolished the increase in MBF produced by ET-1 (10 ng/mln) 
in the normal zone and augmented collateral vessel vasoconstriction. These 
findings indicate that ET-1 induces the endothelial production of PGI2 but not 
NO in the coronary clmulallon and that collateral blood flow is particularly 
dependent on PGI2 production dudng elevations of ET-1. 
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[805-3  1 Endothelin-1 Myocardial Clearance and Production 
and Effect on Capillary Permeabil ity in Vivo 
Jocelyn Dupuis, Cad A. Goresky, Colin P, Rose, Duncan J. Stewart, 
Peter Cemacok. Montreal Heart Institute and Montreal General Hospital, 
Montreal, Canada 
Myocardial extraction ~nd retease of cimulating endothelin-1 (ET-1) have 
never been quantified i, rive. We measured ET-1 myoca,-dial metabolism and 
the effect of pharmacologic doses of FT.1 on myocardial capillary permeabil- 
ity, blood flow and transit imes in the a ,lasthetlzed og by combining indicator 
dilution studies and the dsterminatlo~l of immunoreactive ET-1 levels. The 
myocardium extracted 17.7 -;- 4.6% of tracer ET-1 (N = 12). Simultaneously 
measured ET-1 levels in the asda (0.97 -i- 0.46 pg/ml) and coronary sinus 
(0.96 -4- 0.53 pg/ml) were not significantly different, suggesting a production 
of ET-1 by the head that I~[ances the amount extracted. Intracomnary in- 
fusion of ET-1 (5 ng/kg/mln) ~ncreased coronary sinus ET-1 levels by about 
100-fold (from 1.30 • 0.09 to 136.3~ :t: 11.6.,3 pg/ml) with a approximate 
5-fold increase in systemic levels (flora 1.32 ~ 0.27 to 6,03 4- 1.84 Wml). 
Heart rate and adedal blood pressure did not vary but the infusion caused a 
mild decrease in coronary blond ffow with an increase in myocardial transit 
times (N = 4). The permeability surface area product per interstitial space 
(Ks) for the small molecular weight probe sucrose decreased in a manner that 
was lineady related tothe decrease in myocardial blood ftow (R = 0.917, p = 
0.001). This iypical behaviour of Ks is observed when myocardial capilladas 
are dorecmlted following reductions In coronary blood flow. The available 
capillary surface area, but not the permeability, consequently decreased. We 
conclude that there is a myocardial metabolic balance for ET-1 and that the 
heart marginally contributes to clmulating ET-1. Pharmacologic levels of ET-1 
reduce the exchangeable capillary surface area but do not modify capillary 
pormeabil~. This reduction of mtcroc{rcufatory exchanges in the heart rep- 
resents a novel action of ET-1 that may be important in pathologic ondition;~ 
associated with increased ET-1 levels. 
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~ - ~  Effects of Nitric Oxide Blockade on 
Adenosine-Mediated Coronary  Vasodilation In Pigs 
Robed E. Goidstein, Frededck G. Pantco, Paul A. Pudimat, 
Adam Goldstein. USUHS, Bethesda, MD 
The role of nitric oxide (NO) in determining coronary blood flow remains 
uncertain. Bfood flow stimulates endothelial release of NO. Thus, NO may 
potentiate vasndilatlon bagun by mechanisms unrelated to NO. To examine 
this possibility, we measured the effects of Io~1 blockade of NO synthe- 
sis with Intrasoronary L-nitmarginine methyl ester (L-NAME) on adenosine 
(Ado)-induced coronary vesodilation in open-chested pigs. Test agents ware 
infused directly into the left antedor descending coronary artery. Intrecoro- 
nary L-NAME had no effect on baseline coronary blood flow (CBF) or other 
hemodynamlce. Selective blockade of NO synthesis was shown when L- 
NAME, 5/~g/kg over 20 mtn, Inhibited vasodilatlo;; to bradykinln but failed to 
affect vasedilation to nifmpmaside. 0olus :~lu, 2/~g/kg (n = 6 pigs), raised 
CBP similarly before L-NAME (57% :l: 7 [SE]) and after L-NAME (46% -~ 
6) (p = 0.3). However, continuously infused intracoronary Ado (n = 13 pigs) 
caused the following: 
Ado dose Peak CBF Rise: p (Pro vs. post) 
pro L-NAME post L-NAME 
0.2/~g/kg/min 29% :l: 3 14% 2:1 p < 0.01 
0.6 pgJkg/min 47% 4- 5 32% 2:1- 3 p < 0.02 
2.0/~g/kg/mtn 89%-~ 8 68% 2:7 JO ..: 0,01 
Ado-inducad CBF dse was unchanged after intracomna~/vehicle for L- 
NAME. By contrast, Ado-induced vasodilatlon was consistently diminished 
when Ado was infused steadily a.Cter L-NAME. These data suggest that NO 
release can potentiate coronary flow dses induced by vesodilator egonlsts 
not pdmadly mediated by NO. Release of NO may be a significant secondary 
mechanism that normally amplifies persistent responses to adenosine and 
possibly other vasodilstors involved in metabolic control of CBF. Interference 
with NO release may cause a general decline in coronary flow responsive- 
ness, not just a loss of eificacy of vasodilators pflmadly mediated by NO. 
